Overview

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.

Phase:

Phase 3

Details

Lead Sponsor:

Sage Therapeutics

Treatments:

Citalopram
Desvenlafaxine Succinate
Duloxetine Hydrochloride
Sertraline